Data / Drug companies / Piramal Critical Care Inc
Piramal Critical Care Inc: 41 products in the FDA NDC directory, labeler code 66794
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Piramal Critical Care Inc (labeler code 66794) lists 41 products in the FDA National Drug Code Directory, covering 18 finished drugs by generic name. By type: 39 prescription drugs, 2 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 25, 2026.
The request: Watch Piramal Critical Care Inc (FDA labeler code 66794): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 66794
- Products in commercial distribution
- 41
- Packages
- 48
- Finished drugs by generic name
- 18
- Prescription products
- 39
- Over the counter products
- 0
- Controlled substance products
- Schedule II 2
- Flagged as original packager
- 38 of 38 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- February 28, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 34 | 82.9% |
| New drug applications (NDA) | 4 | 9.8% |
| Bulk ingredients | 2 | 4.9% |
| Other unapproved drugs | 1 | 2.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 39 | 95.1% |
| Bulk ingredients | 2 | 4.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Isoflurane | 4 | 5 |
| Baclofen injection | 4 | 1 |
| Glycopyrrolate | 4 | 64 |
| Zinc sulfate | 3 | 7 |
| Sevoflurane | 3 | 9 |
| Desflurane | 2 | 4 |
| Morphine sulfate | 2 | 31 |
| Levothyroxine sodium | 2 | 44 |
| Rocuronium | 2 | 3 |
| Dexmedetomidine | 2 | 11 |
| Linezolid | 2 | 28 |
| Dexmedetomidine hydrochloride | 2 | 21 |
| Chlorpromazine hydrochloride | 2 | 27 |
| Erythromycin lactobionate | 1 | 4 |
| Pantoprazole sodium | 1 | 54 |
| Succinylcholine chloride | 1 | 27 |
| Doxycycline | 1 | 63 |
| Edaravone | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 18 | 43.9% |
| Liquid | 11 | 26.8% |
| Injection | 9 | 22% |
| Injection, powder, for solution | 2 | 4.9% |
| Injection, powder, lyophilized, for solution | 1 | 2.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Desflurane | 66794-021 | Liquid | Generic drugs (ANDA) | October 25, 2026 |
| Erythromycin Lactobionate | 66794-251 | Injection, powder, for solution | Generic drugs (ANDA) | August 13, 2026 |
| Desflurane | 66794-021 | Liquid | Other unapproved drugs | July 1, 2026 |
| Sevoflurane | 66794-023 | Liquid | Bulk ingredients | September 22, 2025 |
| Chlorpromazine hydrochloride | 66794-250 | Injection | Generic drugs (ANDA) | December 1, 2024 |
| Chlorpromazine hydrochloride | 66794-249 | Injection | Generic drugs (ANDA) | December 1, 2024 |
| Edaravone | 66794-259 | Injection, solution | Generic drugs (ANDA) | July 8, 2024 |
| Linezolid | 66794-236 | Injection | Generic drugs (ANDA) | March 8, 2024 |
| Linezolid | 66794-219 | Injection, solution | Generic drugs (ANDA) | March 8, 2024 |
| Zinc Sulfate | 66794-255 | Injection, solution | Generic drugs (ANDA) | November 30, 2023 |
| Pantoprazole sodium i.v. | 66794-258 | Injection, powder, for solution | Generic drugs (ANDA) | October 10, 2023 |
| Doxycycline | 66794-237 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 5, 2023 |
| Levothyroxine Sodium | 66794-201 | Injection | Generic drugs (ANDA) | October 1, 2022 |
| Levothyroxine Sodium | 66794-200 | Injection | Generic drugs (ANDA) | October 1, 2022 |
| Zinc Sulfate | 66794-240 | Injection, solution | Generic drugs (ANDA) | June 20, 2022 |
| Zinc Sulfate | 66794-239 | Injection, solution | Generic drugs (ANDA) | June 20, 2022 |
| Dexmedetomidine | 66794-233 | Injection, solution | Generic drugs (ANDA) | May 1, 2021 |
| Dexmedetomidine Hydrochloride | 66794-235 | Injection | Generic drugs (ANDA) | April 1, 2021 |
| Dexmedetomidine Hydrochloride | 66794-234 | Injection | Generic drugs (ANDA) | April 1, 2021 |
| Succinylcholine Chloride | 66794-232 | Injection, solution | Generic drugs (ANDA) | January 20, 2021 |
| Dexmedetomidine | 66794-230 | Injection, solution | Generic drugs (ANDA) | January 19, 2021 |
| Sevoflurane | 66794-022 | Liquid | Generic drugs (ANDA) | October 1, 2020 |
| Rocuronium | 66794-229 | Injection, solution | Generic drugs (ANDA) | July 20, 2020 |
| Rocuronium | 66794-228 | Injection, solution | Generic drugs (ANDA) | July 20, 2020 |
| Glycopyrrolate | 66794-205 | Injection, solution | Generic drugs (ANDA) | July 11, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.